Skip to main content
Premium Trial:

Request an Annual Quote

Pressure BioSciences Aims to Raise $5M to Regain Compliance with Nasdaq Listing Requirements

Premium

This article was originally posted on June 14.

Pressure BioSciences said today it has received a notice from Nasdaq granting it an extension until Oct. 3 to regain compliance with the exchange's minimum stockholder equity requirement of $2.5 million.

According to a plan submitted by PBI to Nasdaq on May 23, to regain compliance and remain above the requirement for the foreseeable future, the company will need to raise at least $5 million in additional equity capital. The company was first notified it had fallen out of compliance on April 6.

On April 13, PBI announced it had raised $825,720 in gross proceeds from the sale of 55,048 units to 10 accredited investors including president and CEO Richard Schumacher, in the first tranche of its $6 million Series C private placement.

This tranche "took months longer than expected to close," Schumacher noted in a statement accompanying the raise, estimating that proceeds from the round would "enable [the company] to fund existing operations to approximately June 30, 2011."

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.